Adiponectin, resistin, Interleukine-4, TGF-β2 levels before and after clozapine treatment in a group of first episode, treatment resistant schizophrenia patients

• DOI: 10.1192/j.eurpsy.2023.1326
• Publication Date: 2023-08-08T09:24:31Z
• Authors: P. Petrikis; A. Karampas; G. Leondaritis; D. Archimandriti; P. Spyrou; M. Plakoutsis; G. Georgiou; C. Mantas; P. Voulgari; T. Hyphantis
• Keywords: Resistin

Introduction Treatment resistant schizophrenia (TRS) affects at least 15-20% of newly diagnosed patients with schizophrenia. Clozapine treatment for this sub-group should be considered immediately after the failure in response to two antipsychotics (usually risperidone and olanzapine) received adequate doses time. Immune changes have been reported first episode psychosis, although results from various studies remain inconclusive. Very few investigated so far cytokine adipokine TRS. Objectives To measure Interleukin-4 (IL-4), Tumor Growth Factor-β2 (TGF-β2), adiponectin resistin a sample forty first-episode psychosis (FEP) who proved (TRS),after atypical ( olanzapine risperidone) clozapine treatment. Methods Serum levels adiponectin, resistin, IL-4 TGF-β2 were measured by enzyme linked immunosorbent assay (ELISA) before Psychopathology was assessed Positive Negative Syndrome Scale (PANSS) treatment, BMI calculated days blood collection. Results We observed significant decrease switching olanzapine/risperidone (p<0.0001, Wilcoxon signed rank test W=820.0) statistically increase Wicoxon W=-658.0). Similarly, found (p=0.039, W=-454.0 p=0.029, W=-386.0, respectively). Conclusions Resistin, TGF-β while significantly decrease. The findings may importance, since they reflect specific immune responders. Disclosure Interest None Declared